Amneal Pharmaceuticals IncAMRX
Price$20.14Intrinsic value$14.1430% below price

Valuation

How Intrinsic Value compares with model outputs

Intrinsic Value $14.14median of 6 methods · middle span $9-$17based on filings through 30 Jun 2026
Market Price $20.14Price as of 30 Sep 2026
Margin of Safety -29.8%as of 30 Sep 2026

Valuation methods vs. Market Price

Company vs. peer median Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Assumptions

ParameterValue
Years 1–5: analyst growth pathFive-year total matches analyst consensus exactly. Year 1: 19.5% (near-term consensus, capped) · years 2–5: 20.2%/yr (balance of the path).20.0% per year
Years 6–10: glide to demonstrated growth
Per-year rates
Yr 616.7%Yr 713.3%Yr 89.9%Yr 96.4%Yr 103.0%
20.2% → 3.0%
Years 11–20: glide to long-run rate
Per-year rates
Yr 113.0%Yr 123.0%Yr 133.0%Yr 143.0%Yr 153.0%Yr 163.0%Yr 173.0%Yr 183.0%Yr 193.0%Yr 203.0%
3.0% → 3.0%
Beyond year 20: terminal growthPerpetual long-run rate3.0%
Historical EPS growth (multi-year median)median of 1 window (5y) (limited history)-18.5%
Discount rate (cost of equity) 10.2%
Volatility vs market (adjusted beta)1.17

Valuation Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Assumptions Sandbox Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Compare with peers

Search any company to compare valuation, profitability, returns, growth, and financial strength side by side.

Compare the target company plus 1 peer. Sign in / Sign up to compare a maximum of 3 peers.

Best in rowHigher is betterLower is better—Data not available
TargetAmneal Pharmaceuticals IncAMRXHealth Care
Valuation
P/E42.0×
P/S2.0×
P/B182.8×
EV / Revenue2.8×
EV / EBITDA10.7×
Profitability
Gross margin44.3%
Operating margin19.6%
Net margin5.1%
FCF margin4.1%
Returns
ROE476.5%
ROA4.2%
ROIC6.4%
Growth
Revenue growth (YoY)11.6%
5-yr fwd EPS growth20.0%
Financial strength
Debt / Equity77.83×
Current ratio2.20×
Altman Z-Score2.5
Interest coverage—
Dividend yield—

Best value in each row is highlighted. Figures are periodic snapshots from the same filings used across each dossier; a dash means the figure is not available.

AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.